Edition:
United Kingdom

Biocept Inc (BIOC.OQ)

BIOC.OQ on NASDAQ Stock Exchange Capital Market

0.18USD
23 May 2018
Change (% chg)

$-0.00 (-0.05%)
Prev Close
$0.18
Open
$0.18
Day's High
$0.18
Day's Low
$0.18
Volume
29,272
Avg. Vol
426,227
52-wk High
$1.63
52-wk Low
$0.17

Chart for

About

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally... (more)

Overall

Beta: 3.04
Market Cap(Mil.): $39.03
Shares Outstanding(Mil.): 30.25
Dividend: --
Yield (%): --

Financials

  BIOC.OQ Industry Sector
P/E (TTM): -- 32.19 32.75
EPS (TTM): -1.26 -- --
ROI: -328.01 13.89 14.38
ROE: -550.52 16.72 16.07

BRIEF-Biocept Inc Files For Mixed Shelf Of Up To $50 Million

* BIOCEPT INC FILES FOR MIXED SHELF OF UP TO $50 MILLION – SEC FILING Source http://bit.ly/2wJv6pr Further company coverage:

15 May 2018

BRIEF-Biocept Inc Obtains Patent For A Certain Technology In China

* BIOCEPT OBTAINS PATENT FOR ITS TARGET SELECTOR MOLECULAR BIOMARKER TECHNOLOGY IN CHINA Source text for Eikon: Further company coverage:

29 Mar 2018

BRIEF-Biocept Reports Q4 Loss Of $0.18 Per Share

* BIOCEPT REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

28 Mar 2018

BRIEF-Biocept And Thermo Fisher Scientific Enter Into Technology And Commercial Collaboration

* BIOCEPT AND THERMO FISHER SCIENTIFIC ENTER INTO TECHNOLOGY AND COMMERCIAL COLLABORATION

28 Mar 2018

BRIEF-Biocept Prices $15 Million Public Offering Of 33.3 Mln Shares and Warrants

* BIOCEPT ANNOUNCES PRICING OF $15.0 MILLION PUBLIC OFFERING OF 33,333,333 SHARES OF COMMON STOCK AND WARRANTS TO PURCHASE 33,333,333 SHARES OF COMMON STOCK

26 Jan 2018

BRIEF-Biocept Offers 18.8 Mln Shares Of Common Stock

* BIOCEPT INC FILES TO SAY IT OFFERING 18.8 MILLION SHARES OF ITS COMMON STOCK AND WARRANTS TO PURCHASE SHARES OF COMMON STOCK - SEC FILING

22 Jan 2018

BRIEF-Biocept Inc Says Signed An In-Network Provider Agreement With Wellmark Inc

* BIOCEPT INC - HAS SIGNED AN IN-NETWORK PROVIDER AGREEMENT WITH WELLMARK INC Source text for Eikon: Further company coverage:

18 Dec 2017

BRIEF-Sabby Management LLC Reports A 9.20 Pct Passive Stake In Biocept

* SABBY MANAGEMENT LLC REPORTS A 9.20 PCT PASSIVE STAKE IN BIOCEPT INC AS OF DEC 5 - SEC FILING Source text: (http://bit.ly/2ACbgue) Further company coverage:

06 Dec 2017

BRIEF-Biocept announces pricing of public offering of up to 4,925,936 shares of common stock

* BIOCEPT ANNOUNCES PRICING OF PUBLIC OFFERING OF UP TO 4,925,936 SHARES OF COMMON STOCK

06 Dec 2017

BRIEF-Biocept And UC San Diego Medical Center Announce Clinical Study Collaboration To Demonstrate Utility Of Biocept's Liquid Biopsy Test In Immunotherapy

* BIOCEPT AND UC SAN DIEGO MEDICAL CENTER ANNOUNCE CLINICAL STUDY COLLABORATION TO DEMONSTRATE UTILITY OF BIOCEPT'S LIQUID BIOPSY TEST IN IMMUNOTHERAPY Source text for Eikon: Further company coverage:

28 Nov 2017

Earnings vs. Estimates